Zealand Pharma A/S 2017 SR
The report outlines Zealand Pharma's corporate social responsibility efforts for 2017, focusing on patient-centricity, employee well-being, and ethical research. Key highlights include the introduction of the "Zealand DNA" culture initiative and achieving a 40% female representation on the Board of Directors. The company transitioned toward becoming a fully integrated biotech entity, emphasizing collaborations with patient advocacy groups. Additionally, Zealand Pharma transitioned its electricity supply to 100% wind energy and maintained a strong safety record with zero reportable accidents.
Company: Zealand Pharma A/S
Sector: Manufacturing
Country: Denmark
Year: 2017
Type: SR
Pages: 13
Back to company
Zealand Pharma A/S
Corporate Social Responsibility Report
The report outlines Zealand Pharma's corporate social responsibility efforts for 2017, focusing on patient-centricity, employee well-being, and ethical research. Key highlights include the introduction of the "Zealand DNA" culture initiative and achieving a 40% female representation on the Board of Directors. The company transitioned toward becoming a fully integrated biotech entity, emphasizing collaborations with patient advocacy groups. Additionally, Zealand Pharma transitioned its electricity supply to 100% wind energy and maintained a strong safety record with zero reportable accidents.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities